PHARMACOGENETIC BASES OF INDIVIDUAL SENSITIVITY AND PERSONALIZED ADMINISTRATION OF ANTIPLATELET THERAPY IN DIFFERENT ETHNIC GROUPS
Cardiovascular diseases (CVDs) are the leading cause of disability and mortality worldwide. Increased thrombosis is the trigger point for the development of various CVDs and their complications, and therefore, therapy with P2Y12-receptor inhibitors is always pathogenetically justified and vital. How...
Saved in:
Main Authors: | B. I. Kantemirova, E. A. Orlova, O. S. Polunina, E. N. Chernysheva, M. A. Abdullaev, D. A. Sychev |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute
2021-05-01
|
Series: | Фармация и фармакология (Пятигорск) |
Subjects: | |
Online Access: | https://www.pharmpharm.ru/jour/article/view/768 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
UP TO DATE ANTIPLATELET THERAPY IN PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS AND REAL CLINICAL PRACTICE
by: S. Yu. Martsevich, et al.
Published: (2015-12-01) -
RESISTANCE TO ANTIPLATELET DRUGS IN PATIENTS WITH ISCHEMIC HEART DISEASE
by: D. H. Aynetdinova, et al.
Published: (2015-12-01) -
THE ROLE OF MODERN ANTIPLATELET THERAPY IN PREVENTION OF ATHEROTHROMBOSIS: THE IMPORTANCE OF CLOPIDOGREL AND ITS GENERIC DRUGS
by: O. V. Gaisenok
Published: (2016-01-01) -
Antiplatelet treatment and gastro-intestinal hemorrhage risk
by: D. V. Duplyakov
Published: (2005-08-01) -
MONITORING OF THE EFFECTIVENESS OF ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE
by: N. F. Puchinian, et al.
Published: (2017-03-01)